Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AMDL's cancer test, DR-70, has been shown to more effective at detecting ovarian cancer than the standard diagnostic tool in an experiment carried out by German researchers.
Subscribe to our email newsletter
The researchers, at Johannes Gotenberg University, simultaneously investigated the serum activities of DR-70 and the standard test, CA-125, in 61 preoperative patients with histologically confirmed ovarian carcinoma, and one hundred healthy people.
In the test, DR-70 was shown to be 100% effective in detecting the presence of cancer and 83.6% effective in determining the type of cancer – 13.1% higher than the standard test.
The German researchers concluded that “DR-70 represents a tumor marker with which ovarian carcinoma can be diagnosed at levels of sensitivity and specificity which compare favorably to those measured with CA-125.” The study is published in the German Journal of Obstetrics and Gynecology.
Gary Dreher, AMDL CEO emphasized that the company’s primary objective remains receiving FDA clearance to market DR-70, which would simultaneously increase market awareness and acceptance in the international marketplace.